Hamm, Germany

Fred Bernd Oppermann

This inventor holds 1 USPTO granted patent. Top assignee: Bayer Aktiengesellschaft. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fred Bernd Oppermann: Innovator in Biotechnological Production

Introduction

Fred Bernd Oppermann is a notable inventor based in Hamm, Germany. He has made significant contributions to the field of biotechnological processes, particularly in the production of polyasparaginic acid homopolymers and copolymers. His work has implications for various applications, including the manipulation of crystallization behaviors in aqueous systems.

Latest Patents

Fred Bernd Oppermann holds a patent for "Polyasparaginic acid homopolymers and copolymers, biotechnical production and use thereof." This invention focuses on the biotechnological production of polyaspartic acid homo- and copolymers, which can be utilized to influence the crystallization or agglomeration behavior of sparingly soluble salts or solids in aqueous systems. He has 1 patent to his name.

Career Highlights

Oppermann is associated with Bayer Aktiengesellschaft, a leading global company in the pharmaceutical and life sciences sector. His role at Bayer has allowed him to engage in innovative research and development, contributing to advancements in biotechnology.

Collaborations

Throughout his career, Fred Bernd Oppermann has collaborated with notable colleagues, including Winfried Joentgen and Alexander Steinbüchel. These collaborations have fostered a productive environment for innovation and research.

Conclusion

Fred Bernd Oppermann's contributions to biotechnology through his patented inventions highlight his role as a significant inventor in the field. His work continues to influence the industry and pave the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…